Aimovig(Erenumab-aooe Injection, for Subcutaneous Use)
Aimovig(erenumab-aooe) is a calcitonin gene-related peptide receptor antagonist.
Aimovig is specifically indicated for the preventative treatment of migraine in adults.
Aimovig is supplied as an injection for subcutaneous use. The recommended dosage of Aimovig is 70 mg injected subcutaneously once monthly. Some patients may benefit from a dosage of 140mg injected subcutaneously once monthly, which is administered as two consecutive subcutaneous injections of 70mg each. If a dose of Aimovig is missed, administer as soon as possible. Thereafter, Aimovig can be scheduled monthly from the date of the last dose.
Generic Name and Formulations:
Erenumab-aooe 70mg/mL; soln for SC inj; preservative-free.
Indications for AIMOVIG:
Prophylaxis of migraine.
Give by SC inj into abdomen, thigh, or upper arm. 70mg once monthly; some patients may benefit from 140mg (given as 2 consecutive 70mg inj) once monthly.
Do not inj into tender, bruised, red, or hard areas. Latex allergy. Elderly. Pregnancy. Nursing mothers.
Calcitonin gene-related peptide (CGRP) receptor antagonist.
Inj site reactions, constipation, cramps, muscle spasms.
Single-dose prefilled SureClick autoinjectors—1, 2; Single-dose prefilled syringes—1, 2